Skip to main content
. Author manuscript; available in PMC: 2021 May 19.
Published in final edited form as: Clin Cancer Res. 2019 Jul 1;25(19):5787–5798. doi: 10.1158/1078-0432.CCR-19-0070

Table 3.

CRS-207 infusion–related adverse events by patienta (N = 38)

Infusion-related adverse events Grade 1 n (%) Grade 2 n (%) Grade 3 n (%) Total; n (%)
Chills/rigor 6 (16%) 29 (76%) 2 (5%) 37 (97%)
Pyrexia 21 (55%) 15 (39%) 1 (3%) 37 (97%)
Nausea 21 (55%) 5 (13%) 0 (0%) 26 (68%)
Vomiting 13 (34%) 5 (13%) 0 (0%) 17 (45%)
Hypotension 5 (13%) 1 (3%) 1 (3%) 7 (18%)
a

No grade 4 CRS-207 infusion–related adverse event was observed.